NCT04064814View on ClinicalTrials.gov

Evaluation of Efficacy and Safety of add-on Alpha-lipoic Acid on Migraine Prophylaxis in Adolescent Population

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 14, 2019

Primary Completion Date

April 30, 2021

Study Completion Date

June 30, 2021

Conditions
Adolescent Migraine
Interventions
DRUG

Flunarizine 5mg

Flunarizine 5mg once daily,orally for 12 weeks

DRUG

Alpha lipoic acid 300mg

Alpha lipoic acid 300mg ,once daily ,orally for 12 weeks

Trial Locations (1)

751019

AIIMS, Bhubaneswar

All Listed Sponsors
lead

All India Institute of Medical Sciences, Bhubaneswar

OTHER

NCT04064814 - Evaluation of Efficacy and Safety of add-on Alpha-lipoic Acid on Migraine Prophylaxis in Adolescent Population | Biotech Hunter | Biotech Hunter